Gilead Sciences, Inc (NASDAQ: GILD) has experienced a rise in its stock price by 1.18 compared to its previous closing price of 116.04. However, the company has seen a gain of 2.71% in its stock price over the last five trading days. zacks.com reported 2025-03-07 that Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.
Is It Worth Investing in Gilead Sciences, Inc (NASDAQ: GILD) Right Now?
Gilead Sciences, Inc (NASDAQ: GILD) has a higher price-to-earnings ratio of 319.83x compared to its average ratio, The 36-month beta value for GILD is at 0.33. Analysts have varying views on the stock, with 15 analysts rating it as a “buy,” 5 rating it as “overweight,” 11 as “hold,” and 0 as “sell.”
The public float for GILD is 1.24B, and currently, shorts hold a 1.70% of that float. The average trading volume for GILD on March 10, 2025 was 7.61M shares.
GILD’s Market Performance
GILD stock saw an increase of 2.71% in the past week, with a monthly gain of 17.82% and a quarterly increase of 26.94%. The volatility ratio for the week is 2.51%, and the volatility levels for the last 30 days are 2.33% for Gilead Sciences, Inc (GILD).. The simple moving average for the past 20 days is 8.07% for GILD’s stock, with a 38.85% simple moving average for the past 200 days.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Oppenheimer repeating the rating for GILD by listing it as a “Outperform.” The predicted price for GILD in the upcoming period, according to Oppenheimer is $132 based on the research report published on March 04, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see GILD reach a price target of $120. The rating they have provided for GILD stocks is “Buy” according to the report published on February 18th, 2025.
DZ Bank gave a rating of “Buy” to GILD, setting the target price at $108 in the report published on February 13th of the current year.
GILD Trading at 17.90% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.02% of gains for the given period.
Volatility was left at 2.33%, however, over the last 30 days, the volatility rate increased by 2.51%, as shares surge +19.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.83% upper at present.
During the last 5 trading sessions, GILD rose by +2.71%, which changed the moving average for the period of 200-days by +73.38% in comparison to the 20-day moving average, which settled at $108.64. In addition, Gilead Sciences, Inc saw 27.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from MERDAD V PARSEY, who proposed sale 21,910 shares at the price of $115.70 back on Mar 03 ’25. After this action, MERDAD V PARSEY now owns shares of Gilead Sciences, Inc, valued at $2,534,913 using the latest closing price.
GILEAD SCIENCES, INC., the 10% Owner of Gilead Sciences, Inc, purchase 1,363,636 shares at $11.00 during a trade that took place back on Feb 18 ’25, which means that GILEAD SCIENCES, INC. is holding 31,424,760 shares at $14,999,996 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc stands at 0.02. The total capital return value is set at 0.18. Equity return is now at value 2.28, with 0.79 for asset returns.
Based on Gilead Sciences, Inc (GILD), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 1.38. The interest coverage ratio of the stock is 8.53.
Currently, EBITDA for the company is 1.66 billion with net debt to EBITDA at 3.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.67. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
In conclusion, Gilead Sciences, Inc (GILD) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
